| Overview |
| bs-5373R |
| GIT1(Tyr545) Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Cow, Pig |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human GIT1 around the phosphorylation site of Tyr545 |
| Tyr545 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 28964 |
| Cytoplasm, Cell membrane |
| GIT1 phospho Tyr545; p-GIT1 Tyr545; ARF GAP GIT1; ARF GTPase activating protein GIT1; CAT 1; Cat1; Cool associated and tyrosine phosphorylated protein 1; G protein coupled receptor kinase interactor 1; GRK interacting protein 1. |
| Heterotrimeric G protein-mediated signal transduction is a dynamically regulated process with the intensity of signal decreasing over time despite the continued presence of the agonist (1,2). G protein-coupled receptor kinases (GRKs) are activated by activated G protein-coupled receptors, and they function to phosphorylate and inactivate cell surface receptors in the heterotrimeric G protein signaling cascade (3,4). GIT1 (for GRK-interactor 1) and GIT2 are GTPase-activating proteins (GAP) for members of the ADP ribosylation factor (ARF) family of small GTP-binding proteins, which are involved in vesicular trafficking (5,6). GIT1 overexpression results in reduced internalization and resensitization of b2-adrenergic receptor, thus reducing b2-adrenergic receptor signaling (5). |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz